

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Oncology

**Manuscript NO:** 56865

**Title:** GOECP / SEOR Clinical Recommendations for Lung Cancer Radiotherapy during the CoVID-19 pandemic

**Reviewer's code:** 03552525

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Professor

**Reviewer's Country/Territory:** Japan

**Author's Country/Territory:** Spain

**Manuscript submission date:** 2020-05-17

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2020-05-18 01:25

**Reviewer performed review:** 2020-05-18 03:02

**Review time:** 1 Hour

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
<https://www.wjgnet.com>

## **SPECIFIC COMMENTS TO AUTHORS**

CoVID-19 pandemic is serious problem worldwide, and it is very important to discuss this problem. However, there are some points to revise before publication. 1. SARS-CoV-2 and PCR are abbreviations. Authors should define them. 2. There are no references about lung cancer in paragraph 2 of Introduction section. Authors should add. 3. Authors said that" the division of departmental staff into independent operating groups (i.e., shift-based health care activity); the possibility of working from home; the reorganization of physical resources (waiting rooms, consultations, linear accelerator treatment room) to minimize the number of people in the same place". Could you show concrete example about this for reader to image easily. 4. Authors wrote that" in whom a temporary interruption or delay in starting treatment is unlikely to lead to significant tumour progression". Could you show concrete criteria? 5. In table 1, "DBE" was used. Authors would like to write "BED"? 6. If there are report about what chemotherapy regimen is recommended is resent environment, please tell me about it. 7. If authors have comments about duration of durvalumab after CCRT, please tell me about it. 8. Authors wrote that "PCI could be delayed if brain MRI is used to closely monitor the patient". Could you tell me how long the duration is allowed?

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Oncology

**Manuscript NO:** 56865

**Title:** GOECP / SEOR Clinical Recommendations for Lung Cancer Radiotherapy during the CoVID-19 pandemic

**Reviewer's code:** 05385069

**Position:** Peer Reviewer

**Academic degree:** PhD

**Professional title:** Postdoctoral Fellow, Professor

**Reviewer's Country/Territory:** Iran

**Author's Country/Territory:** Spain

**Manuscript submission date:** 2020-05-17

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2020-05-19 04:17

**Reviewer performed review:** 2020-05-19 04:21

**Review time:** 1 Hour

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
<https://www.wjgnet.com>

#### **SPECIFIC COMMENTS TO AUTHORS**

We found a new conception of radiotherapy and COVID-19 relation in this report. I think it is better to release it because can cause promotion other reports in this issue.

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Oncology

**Manuscript NO:** 56865

**Title:** GOECP / SEOR Clinical Recommendations for Lung Cancer Radiotherapy during the CoVID-19 pandemic

**Reviewer's code:** 03092939

**Position:** Editorial Board

**Academic degree:** MD, PhD

**Professional title:** Assistant Professor, Lecturer

**Reviewer's Country/Territory:** Japan

**Author's Country/Territory:** Spain

**Manuscript submission date:** 2020-05-17

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2020-05-17 23:41

**Reviewer performed review:** 2020-05-19 23:28

**Review time:** 1 Day and 23 Hours

<b>Scientific quality</b>	[ <input checked="" type="radio"/> ] Grade A: Excellent [ <input type="radio"/> ] Grade B: Very good [ <input type="radio"/> ] Grade C: Good [ <input type="radio"/> ] Grade D: Fair [ <input type="radio"/> ] Grade E: Do not publish
<b>Language quality</b>	[ <input checked="" type="radio"/> ] Grade A: Priority publishing [ <input type="radio"/> ] Grade B: Minor language polishing [ <input type="radio"/> ] Grade C: A great deal of language polishing [ <input type="radio"/> ] Grade D: Rejection
<b>Conclusion</b>	[ <input checked="" type="radio"/> ] Accept (High priority) [ <input type="radio"/> ] Accept (General priority) [ <input type="radio"/> ] Minor revision [ <input type="radio"/> ] Major revision [ <input type="radio"/> ] Rejection
<b>Re-review</b>	[ <input type="radio"/> ] Yes [ <input checked="" type="radio"/> ] No
<b>Peer-reviewer statements</b>	Peer-Review: [ <input checked="" type="radio"/> ] Anonymous [ <input type="radio"/> ] Onymous Conflicts-of-Interest: [ <input type="radio"/> ] Yes [ <input checked="" type="radio"/> ] No

#### **SPECIFIC COMMENTS TO AUTHORS**

This paper is a resional guideline for clinical recommendations for lung cancer radiotherapy during the CoVID-19 pandemic. That is well-documented. And there are important aspects for the radiation oncologists and clinicians and worth to be published. Minor comment: In Table 2, please consider to give a unit (Gy) in the regimens (FX row).

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Oncology

**Manuscript NO:** 56865

**Title:** GOECP / SEOR Clinical Recommendations for Lung Cancer Radiotherapy during the CoVID-19 pandemic

**Reviewer's code:** 03724953

**Position:** Editorial Board

**Academic degree:** MD, PhD

**Professional title:** Assistant Professor, Doctor, Surgeon

**Reviewer's Country/Territory:** Taiwan

**Author's Country/Territory:** Spain

**Manuscript submission date:** 2020-05-17

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2020-05-18 13:54

**Reviewer performed review:** 2020-05-31 00:02

**Review time:** 12 Days and 10 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input checked="" type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

#### **SPECIFIC COMMENTS TO AUTHORS**

This article is well prepared and clear to understand. The Oncological Group for the Study of Lung Cancer of the Spanish Society of Radiation Oncology reviews the literature and establishes a series of consensus-based recommendations for the treatment of patients with lung cancer in different clinical scenarios during the present pandemic of COVID-19 crisis. There is no further suggestion and should be published as soon as possible.



## RE-REVIEW REPORT OF REVISED MANUSCRIPT

**Name of journal:** World Journal of Clinical Oncology

**Manuscript NO:** 56865

**Title:** GOECP/SEOR clinical recommendations for lung cancer radiotherapy during the coronavirus disease 2019 pandemic

**Reviewer's code:** 03552525

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Professor

**Reviewer's Country/Territory:** Japan

**Author's Country/Territory:** Spain

**Manuscript submission date:** 2020-05-17

**Reviewer chosen by:** Le Zhang

**Reviewer accepted review:** 2020-07-15 10:44

**Reviewer performed review:** 2020-07-15 10:56

**Review time:** 1 Hour

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

## SPECIFIC COMMENTS TO AUTHORS



7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](https://www.wjgnet.com)

There is no further suggestion.